Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.75 |
| ▸ | GAA | P10253 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | GFER | P55789 | 3/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13514056 | 0.90 | MAPT (0.61) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL15127501 | 0.87 | MAPT (0.79) | MAPTGAALMNAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL31540771 | 0.86 | MAPT (0.57) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL5542804 | 0.86 | MAPT (0.77) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL5542809 | 0.86 | MAPT (1.00) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL6159175 | 0.85 | MAPT (0.56) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL15009153 | 0.85 | MAPT (0.71) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL27456657 | 0.85 | MAPT (0.71) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL2102828 | 0.84 | L3MBTL1 (0.71) | MAPTGAALMNAKDM4EALDH1A1 | |
| SCHEMBL27610366 | 0.84 | MAPT (0.74) | MAPTGAALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| CN-1307156-C | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-28 | — | — | CN | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-10-26 | — | — | US | disclosed |
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6878724-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN-PHARMACEUTICA N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | US | disclosed |
| CN-1449382-A | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-15 | — | — | CN | disclosed |
| EP-1317431-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020501-A2 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | MAPT 4545/4885GAA 476/4885LMNA 888/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885GAA 742/4885LMNA 3015/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 501/4885GAA 940/4885LMNA 3243/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885GAA 742/4885LMNA 3015/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | MAPT 2223/4885GAA 387/4885LMNA 3839/4885 |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | MAPT 4545/4885GAA 476/4885LMNA 888/4885 |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | MAPT 4545/4885GAA 476/4885LMNA 888/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885GAA 698/4885LMNA 3115/4885 |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | SREBF1, LIPC, CPT1A | MAPT 4632/4885GAA 769/4885LMNA 1077/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885GAA 698/4885LMNA 3115/4885 |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | MAPT 4545/4885GAA 476/4885LMNA 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.